Can zegalogue be used for babies with hypoglycemia?

Can Zegalogue treat hypoglycemia in newborns?

Zegalogue (dasiglucagon) is a ready-to-use glucagon analog designed for emergency treatment of severe hypoglycemia in adults and children aged 6 years and older. It is not approved for use in babies under 6 years old.

Does FDA approval cover infants?

The FDA label limits Zegalogue to patients 6 years and older. Clinical studies submitted for approval included children 6–17 years old, but no data supported extension to infants or newborns.

What happens if a hospital tries to use it off-label?

Hospitals sometimes use drugs off-label when no approved option exists. In severe cases, traditional glucagon kits that can be drawn into syringes for smaller doses remain the preferred choice for neonates and infants.

What alternatives exist for newborns?

For infants with hypoglycemia, standard care involves intravenous glucose, frequent feeds, and occasional use of continuous glucagon infusions prepared from conventional glucagon kits. Zegalogue's fixed-dose autoinjector or prefilled syringe is sized for larger children and adults.

When does Zegalogue's patent expire?

Zegalogue's composition-of-matter patent expires in 2030.